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diagnosed in 2000-2003 vs 2008-2010 (for HAART initiation: 62.5% vs 78.2%, 
P<0.01; for VS: 53.4% vs 70.7%, P<0.01, respectively), age <30 vs ≥40 years (57.6% 
vs 71.8%, P = 0.01 and 50.6% vs 66.3%, P<0.01), or non-Hispanic blacks (NHB) 
compared with non-Hispanic whites (NHW) (63.4% vs 67.1%, P = 0.01 and 56.2% 
vs 62.4%, P = 0.01). In multivariable models, patients were more likely to initiate 
HAART sooner if diagnosed after 2000-2003 (adjusted hazard ratios [95% 
confidence intervals] for 2004-2007 and 2008-2010: 1.2 [1.0-1.3] and 1.6 [1.3-1.9]) 
but were less likely to start if age <30 vs ≥40 years (0.8 [0.7-0.9]), NHB vs NHW (0.7 
[0.6-0.9]) and female (0.8 [0.7-1.0]). Similar findings were observed for achieving 
VS after diagnosis with the exception of sex. In an analysis of outcomes after 
HAART initiation, further adjusted for CD4 count and plasma HIV RNA viral load 
(VL) at HAART initiation, NHB compared with NHW were less likely to achieve VS 
after HAART initiation (0.7 [0.6-0.9]), while age and gender were no longer 
significant explanatory factors. CONCLUSIONS: During 2000-2010, starting 
HAART and achieving VS ≤12 months became increasingly more common. 
Adjusting for CD4 and VL at start of HAART, only NHB had decreased likelihood 
of achieving VS after HAART initiation.  
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OBJECTIVES: This study examined the influenza vaccination rates and racial and 
ethnic disparities in receiving influenza vaccinations within the past year among 
community pharmacy users and individuals who did not utilize community 
pharmacies. METHODS: The 2009 Medical Expenditure Panel Survey was 
analyzed. The sample consisted of respondents aged 50 years or older, as per the 
2009 recommendations by the Advisory Committee on Immunization Practices. 
Bivariate analyses and multivariate logistic regression were conducted to 
examine the influenza vaccination rates and disparities in the likelihood of 
receiving influenza vaccinations within past year between non-Hispanic Whites 
(Whites), non-Hispanic Blacks (Blacks) and Hispanics. The influenza vaccination 
rates and the likelihood of receiving influenza vaccinations between community 
pharmacy users and non-users were also examined. RESULTS: The sample 
consisted of 71,135,249 (weighted) community pharmacy users and 20,565,253 
(weighted) non-users. Bivariate analyses found that a greater proportion of 
Whites received influenza vaccinations compared to Blacks and Hispanics, 
among both the community pharmacy users (60.1% vs. 49.1% and 51.7%, 
respectively; P<0.0001) and non-users (41.0% vs. 24.3% and 26.0%, respectively; 
P<0.0001). Adjusted logistic regression analyses found significant racial 
disparities between Blacks and Whites; compared to Whites, Blacks were found 
to have a 19 percent lower likelihood among community pharmacy users (odds 
ratio [OR]: 0.81; 95% CI: 0.69-0.95), and a 34 percent lower likelihood among non-
users (OR: 0.66; 95% CI: 0.46-0.94), respectively, of receiving influenza 
vaccinations. Sociodemographic characteristics and health status accounted for 
the disparities between Hispanics and Whites. Overall, community pharmacy 
users had higher influenza vaccination rates (P<0.0001) and were more likely to 
receive influenza vaccinations compared to non-users (P<0.05). CONCLUSIONS: 
Despite influenza vaccination rates being higher among community pharmacy 
users, there were racial disparities in receiving influenza vaccinations among 
both community pharmacy users and non-users. Increased emphasis on 
educational and awareness campaigns among pharmacists and pharmacy 
patrons is needed.  
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OBJECTIVES: Gender inequality has been identified as a key driver of the HIV 
epidemic by UN AIDS; understanding the gendered nature of the HIV epidemic is 
thus of high policy-relevance. Condom use and communication among sexual 
partners are important strategies for HIV prevention. Previous research on the 
impact of women’s empowerment on the uptake of HIV prevention has either 
focused on economic empowerment only or has left unresolved issues with 
respect to unobserved heterogeneity. METHODS: Using a panel data set of more 
than 1,200 married women in rural Malawi from 1998-2008, this paper shows 
that adequate HIV prevention strategies, i.e. condom use within marriage and 
HIV-related spousal communication, are more widely used as women's 
bargaining power increases. I focus on different dimensions of women’s 
empowerment, namely personal (e.g. education and economic empowerment) 
and interpersonal empowerment (e.g. social status and outside options). 
RESULTS: Among the proxies used for women's empowerment, own income, 
knowledge of other local languages and awareness of exit options from marriage 
are found to play a particularly important role in promoting adequate preventive 
behaviors. The main findings continue to hold after individual-specific fixed 
effects and time dummies are included in order to account for unobserved 
heterogeneity and time trends. CONCLUSIONS: The importance of women’s 
empowerment in fighting the spread of HIV is rarely disputed, yet many 
HIV/AIDS campaigns fail to tackle underlying gender inequalities. The results 
from my analysis suggest that greater emphasis should be placed on women’s 
empowerment in order to effectively combat the spread of the HIV/AIDS 
epidemic, particularly in developing countries.  
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OBJECTIVES: Estimate vaccine coverage with hepatitis B birth dose in children 
under 10 years old in high endemic areas of Colombia. Describe how children are 
vaccinated against Hepatitis B in high endemic areas that are hard to reach due 
to geographical barriers. Evaluate factors associated with adequate vaccination 
of newborns with the Hepatitis B birth dose. METHODS: A cross sectional study 
is being carried out in rural areas of the Colombian Amazon. Vaccination history 
was recorded for 953 children < 10yrs who had a vaccine card. Data were 
recollected in three areas of the Colombian Amazon: Leticia, Puerto Nariño and 
Tarapaca.. Children were considered to have a birth dose if they were vaccinated 
with the monovalent vaccine in the first seven days after delivery. Logistic 
models were used to estimate association of valid vaccination with several 
variables. RESULTS: A total of 79.9% of the children received a birth dose of 
hepatitis B, 38.4% received the vaccine in the first week after delivery; 30.9% 
were vaccinated in the first day and 7.6% in the next seven days. Bivariate 
analysis: Birth dose was associated (p<0.00) to children delivered at a health 
facility, health professional assisting the delivery, children living in households 
with at least one of the following (TV, radio, refrigerator or a boat), children born 
to women with a higher education level. Multivariate analysis: Only delivering at 
a health facility was associated with receiving of the birth dose (OR 26.9 CI 95% 
17.8-40.7) CONCLUSIONS: Our study shows children in rural areas are 
inadequately vaccinated even though they live in a high risk area for hepatitis B 
infection and vertical transmission of the HVB is common. Because all children 
cannot be delivered at a hospital due to geographical barriers new strategies 
need to be studied to vaccinate newborns in the rural areas.  
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OBJECTIVES: To estimate the financial impact of currently uninsured individuals 
infected with chronic hepatitis C (CHC) who will enter the health care system in 
2014 under the Affordable Care Act. METHODS: Uninsured CHC prevalence 
estimates among the US household population were obtained by aggregating 
data from three National Health and Nutrition Examination Surveys (NHANES) 
conducted between 2005 and 2010. Commercial insurance claims data from 2007 
to 2011 were used to estimate the average annualized all-cause direct medical 
cost of a CHC patient. ICD-9 diagnosis codes were used to identify CHC patients. 
All medical service and prescription pharmacy costs were tracked longitudinally 
and subsequently adjusted for inflation and length of enrollment. RESULTS: The 
prevalence rate of CHC among the US household population was 0.89% during 
2005-2010 (95% CI (0.69%, 1.09%)). A total of 40.12% of these individuals were 
uninsured (95% CI (32.02%, 48.21%)). Applying NHANES prevalence rates to US 
Census Bureau’s current population survey data, the estimated 2011 uninsured 
CHC population was 1.1MM. However, only 25% or 275,000 individuals may be 
diagnosed. The average annual medical cost for privately insured diagnosed CHC 
patients was approximately $24,000. Combining the uninsured CHC prevalence 
and cost estimates, the annual direct cost of these currently uninsured 
diagnosed CHC individuals is approximately $6.6B when they enter the health 
system. The overall incremental cost of currently uninsured CHC individuals 
may be even higher due to the cost incurred by the undiagnosed CHC population. 
CONCLUSIONS: A large proportion of CHC infected individuals are currently 
uninsured. When the ACA health insurance mandate takes effect in 2014, this 
population will gain access to health care coverage and could substantially 
increase the cost to the health care system.  
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OBJECTIVES: Several randomized studies confirmed the efficacy and safety of 
peginterferon-based antiviral therapy for patients with hepatitis C virus 
infection. However, various types of patients who were not included in those 
studies are possibly seeking antiviral therapy in daily practice. The study aim 
was to analyze those patients and their treatment situation in a real-world 
setting. METHODS: A large claims database (Medical Data Vision, Japan; 4/2010 - 
6/2012) was retrospectively analyzed. The study patients were those who had 
evidence of CHC (ICD10: B182) and initiated either the combination therapy with 
peginterferon + ribavirin (PR) or the triple therapy with peginterferon + ribavirin 
+ telaprevir (PR+T) from November, 2011. RESULTS: A total of 207 patients were 
identified, with 136 patients initiating PR (median age 56 years) and 71 patients 
initiating PR+T (median age 60 years). A quarter of patients were aged ≥65 in both 
therapy groups. 6% of patients given PR and 13% of patients given PR+T were 
previously diagnosed with hepatocellular carcinoma (HCC). Mean initial doses of 
peginterferon and ribavirin were similar between PR and PR+T however, mean 
adherence to the ribavirin dose in PR+T was 78% and lower than PR (95%). 
Patients requiring hospitalizations for treatment initiation were significantly 
different between PR and PR+T (71% vs. 93%, P<0.01); lengths of stay were 11.8 
and 18.5 days in PR and PR+T, respectively (P<0.01), P-values were not changed 
after adjusting for patient age, gender, and previous diagnosis of HCC and 
cirrhosis. CONCLUSIONS: The study found that a quarter of patients were elderly 
and the majority of patients required hospitalization to start treatment with 
either PR or PR+T. More effective and safer treatment is desirable. Further 
